GeneDx Holdings Corp. (WGS)
NASDAQ (NGS) NASDAQ (NGS) Primary 
GENEDX HOLDINGS (WGS) Upgraded to Strong Buy: Here's What You Should Know
GENEDX HOLDINGS (WGS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Reviewing GeneDx Holdings: Exome Testing And EPIC Aura Integration Make It A GARP 'Buy'
GeneDx excels in comprehensive genome and exome testing using a vast genetic database linking 400+ diseases. The company cuts diagnostic times from years to days, enhancing patient outcomes and reducing healthcare costs. WGS basically targets a $45 billion genetic testing market with growth in pediatric, NICU, and adult segments via EPIC Aura integration.
GeneDx CEO on pediatric genetic testing, future of genome sequencing and share surge
Katherine Stueland, GeneDx CEO, joins 'Closing Bell' to discuss company earnings and the future of genome sequencing.
GeneDx Holdings Corp. (WGS) Q4 2024 Earnings Call Transcript
GeneDx Holdings Corp. (NASDAQ:WGS ) Q4 2024 Results Conference Call February 18, 2025 8:30 AM ET Company Participants Sabrina Dunbar - Investor Relations Katherine Stueland - President and Chief Executive Officer Kevin Feeley - Chief Financial Officer Conference Call Participants Dan Brennan - TD Cowen William Bonello - Craig-Hallum Capital Group Matt Stanton - Jefferies Matt Sykes - Goldman Sachs Mark Massaro - BTIG Brandon Couillard - Wells Fargo Operator Good day, and thank you for standing by. Welcome to the GeneDx Fourth Quarter 2024 Earnings Conference Call.
GeneDx Holdings Corp. (WGS) Q4 Earnings and Revenues Surpass Estimates
GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.20 per share. This compares to loss of $0.59 per share a year ago.
GeneDx: Even After Up 2,700% in 2024, Upside Is Still in Play
A little-known stock started to make a huge name for itself in 2024. That stock is GeneDX NASDAQ: WGS.
GeneDx Holdings: A Phenomenal Comeback With More Room To Run
GeneDx Holdings Corp. experienced a dramatic turnaround in 2024, achieving profitability and 100x returns, driven by reduced cash burn and strategic product innovations. Key growth catalysts include the NICU market expansion and pediatric neurology diagnostics, supported by faster turnaround times, non-invasive testing, and EHR integration. Financial improvements include a 44% revenue increase, higher reimbursement rates, and improved gross margins, positioning GeneDx favorably among its peers.
GeneDx Holdings (WGS) Surges 13.2%: Is This an Indication of Further Gains?
GeneDx Holdings (WGS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
This Once Ultracheap Biotech Stock Rockets 2,762%, Nears Buy Point After Big Earnings Win
Biotech stock GeneDx soared 50% after earnings on Oct. 29. Shares of the genetic testing company have soared 2,762% year to date.
Meet the Healthcare Stock That Produced Nvidia-Sized Gains in Less Than a Year
Meet the Healthcare Stock That Produced Nvidia-Sized Gains in Less Than a Year
GeneDx Holdings: Phenomenal Gains, More Upside Potential In Medium Term
GeneDx Holdings Corp. stock has risen by a scarcely believable >3,000% across the past year. The company provides exome sequencing products that can be used to search for and diagnose hundreds of genetic conditions. The company's Q3 earnings led to a >50% uplift in the share price this week, with ~$287 revenues pledged for 2024, and a gross margin of >60%.
GeneDx Holdings Corp. (WGS) Q3 2024 Earnings Call Transcript
GeneDx Holdings Corp. (NASDAQ:WGS ) Q3 2024 Earnings Conference Call October 29, 2024 8:30 AM ET Company Participants Sabrina Dunbar - Investor Relations Katherine Stueland - President and Chief Executive Officer Kevin Feeley - Chief Financial Officer Conference Call Participants Daniel Brennan - TD Cowen William Bonello - Craig Hallum Capital Group Mark Massaro - BTIG Matthew Sykes - Goldman Sachs Group, Inc. Brandon Couillard - Wells Fargo Securities Matthew Stanton - Jefferies Operator Thank you for standing by, and welcome to the GeneDx Third Quarter 2024 Earnings Conference Call. At this time all participants are in a listen-only mode and after the speaker's presentation we will have a question-and-answer session Keep in mind that this call is being recorded.
